This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Thymidylate synthase	An SAR study identified a series of phenacylhomoserine lactone analogs based on 3-oxo-dodecanoyl-L-homoserine lactone (ODDHL) that could be used to treat cancer. A side effect of the chemotherapeutic agent ODDHL is nosocomial <i>Pseudomonas aeruginosa</i> infection. The lead analog displayed strong <i>in vitro</i> inhibition of cancer growth with minimal potential for bacterial infection. Next steps include testing the analogs in animal cancer models. SciBX 2(11); doi:10.1038/scibx.2009.441 Published online March 19, 2009	Analogous covered by a pending U.S. patent application; available for licensing	Oliver, C. <i>et al. J. Med. Chem.</i> ; published online March 4, 2009; doi:10.1021/jm8015377 Contact: Janice R. Sufrin, Roswell Park Cancer Institute, Buffalo, N.Y. e-mail: Janice.sufrin@roswellpark.org